908 Devices
MASS · NASDAQ
$11.51+$0.08 (+0.70%)TodayMarket closed ·
Prev close $11.43
About MASS
- Employees
- 172
- Headquarters
- Burlington, Massachusetts
- Listed
- Dec 18, 2020
- Sector
- Information Technology
- Industry
- Electronic Equipment, Instruments & Components
- Website
- 908devices.com
Leadership
| Name | Title | Since |
|---|---|---|
| E. Kevin Hrusovsky | — | — |
| Kevin Knopp | — | 2012 |
| Christopher Brown | — | 2012 |
| Joseph Griffith | — | — |
| Michael Turner | — | — |
| Barbara Russo | — | — |
| Don Osmer | — | — |
| Jon Frattaroli | — | — |
| John Kenneweg | — | 2019 |
| Kevin Mccallion | — | — |
| Keith Crandell | — | — |
| Fenel Eloi | — | — |
| Tony Hunt | — | — |
| Michele Leonhart | — | — |
| Mark Spoto | — | — |
| Brandi Vann | — | — |
Revenue by product and region
Fiscal year ended Dec 31, 2025: $56.20M total revenue
By product
- Product [Member]$43.28M77.0%
- Consumables and service$12.92M23.0%
By region
- UNITED STATES$41.25M73.4%
- Europe, Middle East and Africa$10.43M18.6%
- Asia Pacific$3.00M5.3%
- Continents of North and South America, excluding the United States.$1.52M2.7%
Suppliers and customers
Price correlation is over one year: 1 means the stocks move together, -1 opposite
| Company | Relationship | Correlation |
|---|---|---|
| Biogen BIIB | Customer | 0.88 |
| WuXi AppTec Co H | Customer | 0.83 |
| Bio-Techne TECH | Supplier and customer | 0.79 |
| Sartorius Vz SRT3.DE | Customer | 0.62 |
| Teva Pharmaceutical Inds TEVA | Customer | 0.62 |
| Takeda Pharmaceutical | Customer | 0.23 |
| Novartis NOVN.SW | Customer | 0.07 |
| Amgen AMGN | Customer | -0.26 |
| Merck & Co MRK | Customer | -0.39 |
| Bristol-Myers Squibb BMY | Customer | -0.46 |
Similar companies
Companies in the same industry as 908 Devices
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.